Paper Details

  1. Home
  2. Paper Details

WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.

Author: ClarkLuciana Go, ClarkOtavio Augusto Camara, SasseAndre D, SasseEmma C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Malignant melanoma, a serious type of skin cancer, is increasing worldwide. Surgery is the main treatment for early stages, but advanced melanoma is often difficult to treat. While new therapies show promise, they are often associated with more side effects and cost. This review investigates whether combining chemotherapy and immunotherapy is a better treatment option for melanoma compared to chemotherapy alone.
Paper Details　
Original Abstract of the Article :
Malignant melanoma, one of the most aggressive of all skin cancers, is increasing in incidence throughout the world. Surgery remains the cornerstone of curative treatment in earlier stages. Metastatic disease is incurable in most affected people, because melanoma does not respond to most systemic tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491196/

データ提供：米国国立医学図書館（NLM）

Chemoimmunotherapy for Metastatic Melanoma: Exploring New Frontiers

This study examines the effectiveness of chemoimmunotherapy, a combination of chemotherapy and immunotherapy, in treating metastatic melanoma. The researchers aimed to determine if this approach offers any advantage over chemotherapy alone. This research is a timely exploration in the battle against this aggressive form of skin cancer, as new approaches are needed to improve treatment outcomes.

Chemoimmunotherapy - An Untapped Potential

This research underscores the need for continued exploration of chemoimmunotherapy as a potential treatment for metastatic melanoma. The study suggests that the combination of chemotherapy and immunotherapy may offer a more potent approach, leading to potentially better treatment outcomes for patients.

Fighting Back: Melanoma and the Need for Innovation

This study highlights the ongoing struggle to find effective treatments for metastatic melanoma. The search for new approaches, such as chemoimmunotherapy, is essential to improving patient outcomes and offering hope for a future with better treatment options.

Dr. Camel's Conclusion

In the face of challenging diseases like metastatic melanoma, researchers are constantly pushing the boundaries of medicine. This study, although retracted, highlights the ongoing quest to discover more effective and innovative treatment strategies. The journey towards a cure for melanoma is long and arduous, but the pursuit of new approaches, like chemoimmunotherapy, gives us reason to believe that progress is possible.
Date :
  1. Date Completed 2018-03-13
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

29409139

DOI: Digital Object Identifier

PMC6491196

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.